Luke Noon is a principle investigator and head of the Metabolic Growth Signals and Regenerative Medicine Laboratory at the CIPF research institute (Valencia, Spain). He has an undergraduate degree from The University of Durham (UK), MSc from Imperial College London (UK) and a Ph.D. in endocrinology performed at St Bartholomew’s Hospital (QMUL, UK). Prior to embarking on his career as group leader, his post-doctoral training took him from London to New York via Valencia, Spain.
Dr Noon started as a CRUK-funded postdoc at the MRC Laboratory for Molecular Cell Biology (UCL) under the mentorship of Professor Alison Lloyd, where their work helped shed new light on glial cell plasticity and peripheral nerve regeneration. Combining his experience in tissue biology and endocrinology, Dr Noon joined the CIBERDEM (Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre, Valencia, Spain) where he forged a path to scientific independence under the tutelage of Dr Deborah Burks, by focusing on how insulin resistance impacts tissue repair in the liver. After receiving a Marie Curie Fellowship in 2012, Dr Noon moved to the laboratory of Professor Scott Friedman at the Icahn School of Medicine at Mount Sinai. Subsequently, he was integrated into the prestigious Ramón y Cajal program (MINECO, Spain) enabling him to start his laboratory. The group has recently been consolidated within the Generation Talent (GenT) program of the Valencian Community (Spain).
Dr Noon’s laboratory explores how metabolic endocrine signals are locally integrated by stromal and epithelial components of the tissue repair machinery. Their aim is to provide new mechanistic insights into the known links between metabolic disease and tissue dysfunction in organs such as the liver.
